Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00137930 | Aug → Nov 2005 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00139334 | Jun 2005 → Jan 2006 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01171963 | Aug 2010 → May 2012 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00382772 | Nov 2006 → Apr 2007 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00289172 | Feb → Sep 2006 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00169455 | Mar → Dec 2005 | Rotavirus infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RIX4414 | “Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine (RIX4414 at 106.5 CCID50) When Given Concomitantly With OPV...” NCT00139334 ↗4“For the first time in China, we assessed the efficacy of two oral doses of the human rotavirus vaccine (RIX4414) in infants during the first two years of life (113808/NCT01171963).” PMID 24013441 ↗ Sep 2013 “GSK Biologicals' Oral Live Attenuated Human Rotavirus Vaccine (RIX4414) as Primary Dosing of Healthy Infants in India Aged Approximately 8 Wks at the Time of the First Dose” NCT00289172 ↗ “The lyophilized formulation of the human rotavirus vaccine, RIX4414 (RotarixTM), is recommended to be stored at 2°C-8°C for optimal immunogenicity.” PMID 21228629 ↗ Jan 2011 “The lyophilized formulation of a human rotavirus vaccine, Rotarix™ (RIX4414) is highly immunogenic.” PMID 21238572 ↗ Jan 2011 |
| Known as | Rotarix | “The lyophilized formulation of a human rotavirus vaccine, Rotarix™ (RIX4414) is highly immunogenic.” PMID 21238572 ↗ Jan 2011 |
| Known as | RotarixTM | “The lyophilized formulation of the human rotavirus vaccine, RIX4414 (RotarixTM), is recommended to be stored at 2°C-8°C for optimal immunogenicity.” PMID 21228629 ↗ Jan 2011 |
| Modality | Vaccine | “Oral Live Attenuated HRV Vaccine” NCT00139334 ↗ |
| Route | Oral | “human rotavirus vaccine RIX4414 oral suspension” PMID 21238572 ↗ Jan 2011 |